IDXX vs ZTS

IDEXX Laboratories trades at a premium valuation with a P/E of 54.63 and forward P/E of 57.69, reflecting its elite profitability and consistent earnings outperformance. The company has delivered 21 of the last 25 quarters with positive EPS surprises, including a 10% beat in the most recent quarter, underpinning strong execution and demand tailwinds in the veterinary diagnostics space. Despite insider selling activity totaling $40.92M over the past six months, the robust growth trajectory, sector-leading ROE of 64.63%, and favorable peer context—especially against lower-growth but cheaper names like ZTS—support continued outperformance. Price momentum remains strong, with a 1Y return of +62.9%, significantly outpacing the healthcare sector average and validating market confidence in sustained earnings growth.

Zoetis Inc. (ZTS) presents a compelling investment opportunity despite near-term price underperformance, with shares down 29.9% over the past year. The company demonstrates exceptional profitability, including a 39.33% operating margin and 49.87% ROE—both materially above sector averages—while maintaining consistent earnings growth and a strong track record of beating estimates in 3 of the last 4 quarters. Valuation remains attractive relative to peers, trading at a forward P/E of 19.06 versus the sector average of 43.86, creating significant margin of safety. Analysts reflect this optimism with a $170.63 target price, implying ~41% upside, supported by durable cash flows and a disciplined capital allocation strategy including a sustainable 1.66% dividend yield.